Skip to main content
Retour
KURA logo

Kura Oncology, Inc.

Qualité des données : 100%
KURA
NASDAQ Healthcare Biotechnology
8,32 €
▲ 0,06 € (0,73%)
Cap. Boursière : 734,90M
Fourchette du Jour
8,05 € 8,52 €
Fourchette 52 Semaines
5,41 € 12,49 €
Volume
1 405 898
Moyenne 50J / 200J
8,55 € / 8,54 €
Clôture Précédente
8,26 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -2,6 0,4
P/B 4,2 2,9
ROE % -94,8 3,7
Net Margin % -413,0 3,9
Rev Growth 5Y % 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
28,20 € +238.9%
Low: 15,00 € High: 40,00 €
BPA Prévisionnel
-3,52 €
CA Est.
120 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 3,93 €
0,75 € – 11,59 €
1,3 B 3
FY2029 0,74 €
0,14 € – 2,18 €
740 M 3
FY2028 -1,44 €
-3,62 € – 3,48 €
410 M 9

Points Clés

Debt/Equity of 0,12 — conservative balance sheet
Negative free cash flow of -70,70M
Capital efficient — spends only 9,84% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)25,24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-94,82%
ROIC-117,03%
Net Margin-412,95%
Op. Margin-449,94%

Sécurité

Debt / Equity
0,12
Current Ratio6,06
Interest Coverage-200,81

Valorisation

P/E Ratio
-2,64
P/B Ratio4,22
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 25,24% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 67,48M Net Income (TTM) -278,67M
ROE -94,82% ROA -37,74%
Gross Margin 99,92% Operating Margin -449,94%
Net Margin -412,95% Free Cash Flow (TTM) -70,70M
ROIC -117,03% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,12 Current Ratio 6,06
Interest Coverage -200,81 Dividend Yield 0,00%
Valuation
P/E Ratio -2,64 P/B Ratio 4,22
P/S Ratio 10,89 PEG Ratio -0,06
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 734,90M Enterprise Value 606,26M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 67,48M 53,88M 0,0 0,0 0,0
Net Income -278,67M -173,98M -152,63M -135,84M -130,47M
EPS (Diluted) -3,18 -2,02 -2,08 -2,03 -1,97
Gross Profit 67,43M 53,88M -849 000,0 0,0 0,0
Operating Income -303,63M -193,20M -165,80M -139,87M -131,26M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 738,36M 760,16M 448,94M 456,31M 534,05M
Total Liabilities 564,23M 346,52M 51,66M 36,03M 27,44M
Shareholders' Equity 174,14M 413,64M 397,27M 420,28M 506,61M
Total Debt 20,46M 16,59M 17,20M 14,02M 6,88M
Cash & Equivalents 149,10M 224,46M 37,32M 51,80M 90,67M
Current Assets 708,66M 744,83M 432,48M 446,43M 522,29M
Current Liabilities 116,97M 78,71M 35,26M 24,06M 22,46M